• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Complementary medicine in uro-oncology
Urologe A. 2021 Jun 15. doi: 10.1007/s00120-021-01584-8. Online ahead of print.ABSTRACTComplementary and alternative medicine (CAM) is widespread in oncology patients with a user rate of approximately 40-50%. An accompanying supportive effect can arise through improved adherence, especially in long-term (e.g. endocrine) therapies through active patient involvement. When assessing the evidence on frequently requested methods, there is no high-quality evidence that homeopathy or anthroposophy leads to an improved prognosis. Mistletoe therapy can be considered to improve the quality of life, although the data quality is weak....
Source: Der Urologe. Ausg. A - June 15, 2021 Category: Urology & Nephrology Authors: Jutta H übner Ralph M ücke Oliver Micke Christian Keinki Source Type: research

Prevalence and expectations of "alternative and complementary medicine" use during radiotherapy in 2016: A prospective study.
CONCLUSION: Alternative and complementary medicines are used more by women, and by patients who used them before radiotherapy. The desired effects are mainly to reduce the side effects of the treatments. More than 80% of patients, whether or not they use alternative and complementary medicine, demand medical information. PMID: 30197027 [PubMed - as supplied by publisher]
Source: Cancer Radiotherapie - September 6, 2018 Category: Cancer & Oncology Authors: Dupin C, Arsène-Henry A, Charleux T, Haaser T, Trouette R, Vendrely V Tags: Cancer Radiother Source Type: research

Importance of complementary medicine approaches for patients with prostate cancer.
CONCLUSION: The results show that prostate cancer patients use a range of CM and have a need for information about CM. Prostate cancer patients are in a special situation because of a regular feedback on the prostate-specific antigen (PSA) value. This should be taken into consideration in consultation with prostate cancer patients regarding CM. PMID: 25297489 [PubMed - as supplied by publisher]
Source: Der Urologe. Ausg. A - October 10, 2014 Category: Urology & Nephrology Authors: Gschwendtner KM, Klein G, Güthlin C, Holmberg C, Horneber M, Weis J Tags: Urologe A Source Type: research